Business Context and Reporting Period
Company: Radiopharm Theranostics Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 22, 2025
Reporting Period: Month of October 2025
Context: The filing serves to disclose a Public Notice issued to the Australian Securities Exchange regarding the "Notice of Annual General Meeting/Proxy Form."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural disclosure regarding a corporate meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The filing is limited to the notification of an upcoming Annual General Meeting.
Guidance, Outlook, and Risks
Management Commentary: The Company published a notice titled "Notice of Annual General Meeting/Proxy Form."
Risks and Contingencies: The filing includes a standard disclaimer stating that the report and its exhibits shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly set forth by specific reference.
Unusual Items: None reported.
Key Facts for Investor Verification
- The filing is a procedural notice for the Annual General Meeting, not a financial results report.
- No financial performance data (revenue, earnings, cash flow) is included in this specific Form 6-K.
- Investors should refer to the attached Exhibit 99.1 for details regarding the Annual General Meeting and proxy voting.
- The document was signed by Phillip Hains, Company Secretary, on October 22, 2025.